| Date | Title | Description |
| 18.09.2026 | Healthcare’s Semantic AI Blind Spot: Why LLMs Cannot Replace Deterministic Data Infrastructure | Glynn Dennis, PhD, Chief Science Officer, Kythera Labs
Healthcare AI has reached an inflection point. AI is rapidly moving from isolated demonstrations to production systems embedded in clinical, operational, and research workflows. A new g... |
| 16.09.2026 | Safer, Stronger, Built in America: President Trump’s Record in North Carolina | President Donald J. Trump returns to North Carolina today with a simple message: North Carolinians are better off with Republican leadership. Since taking office, the Trump Administration has driven crime down, put money back in workers’ po... |
| 11.09.2026 | 2026 World Laureates Foundation Prize Unveiled in Shanghai | 11 WLF Prize laureates; the first time scientists of Chinese descent have been awarded; inaugural WLF Prize for Young Scientists launched.
SHANGHAI, Sept. 11, 2026 /PRNewswire/ -- A news report from Yicai Global:
On the morning of September... |
| 09.09.2026 | Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer | Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently exist
SYDNEY, Sept. 9, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ... |
| 31.08.2026 | Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore | Columvi (glofitamab) will be added to the Cancer Drug List (CDL) and Medication Assistance Fund (MAF) on 1 September 2026 for eligible patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for aut... |
| 28.08.2026 | Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering | SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restor... |
| 28.08.2026 | Anthropic previews new standard to streamline AI-to-machine connections | Anthropic has launched a research preview of its Model Hardware Standard (MHS), a shared specification designed to let AI agents safely control lab instruments and factory equipment. The company claims MHS reduces the time required to integ... |
| 28.08.2026 | DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform | Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical development and global commercialization
DUPAC, one of the DualityBio's fou... |
| 28.08.2026 | China's DualityBio Rises After Forging USD1 Billion Cancer Drug Tie-Up With Roche Unit | (Yicai) Aug. 28 -- Shares of Duality Biotherapeutics rose after it said it has agreed to co‑develop next‑generation antibody‑drug conjugates for multiple oncology indications with Genentech, a subsidiary of Switzerland's Roche, based on the... |
| 28.08.2026 | Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer | Durable Complete Metabolic Response Ongoing Since November 2025
All Evaluable Patients Demonstrated Reductions in Metastasis-Associated CTC Clusters and Terminally Exhausted T cells, With Median Reductions of 83% and 51% Respectively
No Tre... |
| 28.08.2026 | Kazia Therapeutics Limited Announces Proposed Public Offering | SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restor... |
| 24.08.2026 | Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy | HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including obesity
Total deal value of up to $2.3 billion, including upfront, milestone payments and... |
| 11.08.2026 | ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer | ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the appointments of Jim Wassil, currently Chief Operating Off... |
| 06.08.2026 | - | Roche's LightCycler® 480
Roche's LIghtCycler® PRO
"Understanding disease outbreaks and how they spread can have a huge impact on public health," said Dan Malarek, President and CEO, Roche Diagnostics North America. "Our robus... |
| 24.07.2026 | ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406 | SHANGHAI, July 24, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK0406, a novel long-acting ant... |
| 14.07.2026 | Converging at BIO, ACROBiosystems Connects Emerging Innovation Assets with Global Strategic Opportunities | SAN DIEGO, July 14, 2026 /PRNewswire/ -- Ahead of the BIO International Convention, BIOSeedin Summer Innovation Partnering Summit was successfully held at Wyndham San Diego Bayside, California. Hosted by bioSeedin, the summit's discussion t... |
| 29.06.2026 | Lycia Therapeutics Raises $75 Million Series D To Advance LYTAC Pipeline | Lycia Therapeutics announced that it has completed an oversubscribed $75 million Series D financing. The financing was co-led by existing investor Janus Henderson Investors and new investor Balyasny Asset Management. The round also included... |
| 09.06.2026 | PDA Announces Glenn E. Wright is Stepping Down as CEO & President on June 30, 2026; Craig Elliott Assuming Role Effective July 1, 2026 | After 37 years of dedicated service to PDA and its members, Glenn E. Wright steps down as President & CEO effective June 30, 2026. Craig Elliott has been selected by the Board of Directors to fill the role starting July 1.
BETHESDA, Md.... |
| 26.05.2026 | Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer | Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability Data
SYDNEY, May 26, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company")... |
| 09.04.2026 | AI Pioneers Unite to Launch the Shared AI License Foundation to Advance Foundation Model Innovation | A new coalition of technology and innovation leaders has launched the Shared AI License Foundation (SAIL), the first organization dedicated to safeguarding AI innovation through a collaborative patent network. This initiative, led by foundi... |
| 17.03.2026 | Roche Launches NVIDIA AI Factory to Accelerate the Development of New Therapeutics and Diagnostics Solutions | Roche announced that an expansion of its global AI infrastructure, deploying a large-scale AI factory powered by a full stack of the latest-generation NVIDIA accelerated computing and AI. Featuring 2,176 high-performance GPUs on premises ac... |
| 27.02.2026 | BreezeBio: $60 Million Series B Raised To Advance Precision Genetic Medicines Pipeline | BreezeBio, formerly known as GenEdit, has closed $60 million in Series B financing to advance its first internal therapeutic programs toward the clinic and expand its NanoGalaxy delivery platform.
The South San Francisco-based biotechnology... |
| 26.02.2026 | BreezeBio Closes Series B Funding | BreezeBio, (fka as GenEdit), a San Francisco, CA-based biotechnology company developing genetic medicines, raised an undisclosed amount in Series B funding.
The round was led by Yuanta Investment and DSC Investment, with participation from ... |
| 26.02.2026 | Novartis, Genentech file suit alleging illegal importation of prescription drug | Novartis and Genentech are suing a U.S. company and a Canadian pharmacy over the importation of a Canadian version of their allergy medicine.
The importation of the drug, which has strict shipping and temperature controls, potentially puts ... |
| 16.02.2026 | ZAKA VC Backs DeepSeq.AI’s Functional Approach to Protein Drug Discovery | ZAKA VC backs DeepSeq.AI’s hyperscaled functional data application for AI-driven protein drug discovery The founding team combines AI innovation, biological screening, and commercial biotech leadership The platform focuses on function, not ... |
| 12.02.2026 | Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF | SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for AK3280, a ... |
| 05.02.2026 | Startups make leadership changes amid growth |
Loft Dynamics, the pioneer behind the world’s first EASA- and FAA-qualified virtual reality (VR) flight simulators, has appointed Sebastien Borel as chief executive officer, succeeding Founder Fabi Riesen who will serve as chief technology... |
| 04.02.2026 | Genentech Awards Grant to Support Science Center's Translation Project | One-year grant will support activities designed to close the gap between breakthrough innovation and patient impact
PHILADELPHIA, Feb. 4, 2026 /PRNewswire-PRWeb/ -- The Science Center, a premier catalyst of entrepreneurial activity, healthc... |
| 02.02.2026 | SanegeneBio Announces RNAi Global Licensing Collaboration with Genentech | - SanegeneBio grants exclusive worldwide license to one of its RNAi programs to Genentech
- SanegeneBio to receive $200 million upfront payment and will be eligible to receive development and commercialization milestone payments, totaling u... |
| 30.01.2026 | PharmNovo enhances its Board ahead of Phase II development | PharmNovo enhances its Board ahead of Phase II development
Fri, Jan 30, 2026 08:04 CET Report this content
PharmNovo AB announces changes to its Board of Directors, welcoming two new members as the company prepares for its next phase of cli... |
| 27.01.2026 | Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer | SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (S... |
| 26.01.2026 | [Opinion] 2026: The Dawn of AI-Driven Drug Development | (Yicai) Jan. 23 -- The next big leap for artificial intelligence in healthcare is no longer in the lab, but in clinical trials -- where drug development succeeds or fails.
For years, the conversation around AI in healthcare has been dominat... |
| 26.01.2026 | Divamics Showcases Lead Autoimmune Program DVI-001 and Unveils New Metabolic Program DVI-004 at JPM Week 2026 | SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- Divamics (DIVAMICS), an AI-driven biotechnology company specializing in high-precision molecular discovery, highlighted the significant advancement of its internal pipeline during the Biotech Sho... |
| 08.01.2026 | Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD | SHANGHAI, Jan. 8, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidat... |
| 06.01.2026 | Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD | SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidat... |
| 20.12.2025 | US Drug Prices Face Seismic Shift: Pharma Giants Negotiate Deep Cuts | The American healthcare landscape is transforming. US drug prices, long the world's highest, face unprecedented pressure. President Trump drove an aggressive campaign to lower prescription costs. His administration pushed the Most Favored N... |
| 19.12.2025 | Trump announces lower drug price deals with 9 pharmaceutical companies | Getting your Trinity Audio player ready...
By SALLY HO
U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S. Related Articles
Michael Jackson, Diana Ross and ... |
| 11.12.2025 | Medra, a developer of AI-powered lab robots and scientists to advance drug discovery, raises $52M
Send us a News Tip
EXTRACT THE SIGNAL FROM THE NOISE
Cookies | Medra, an artificial intelligence startup focused on drug discovery, has raised $52 million in early-stage funding to try to integrate powerful large language models with physical systems that can perform real-world lab experiments and trul... |
| 10.12.2025 | Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including... | First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions in circulating tumor cells (CTC) and clusters
Reinvigoration of immune system + turning cold tumors hot
Preliminary ex-vivo data in HER2+ pa... |
| 08.12.2025 | Hammerspace Helps Launch the Single Namespace Working Group (SNS) to End Data Fragmentation and Expose a Single, Unified Intelligence Layer for Data | 34-Member Consortium Led by Guardant Health Drafts First Open Standard for Exabyte-Scale Data Access Across Global Environments
SAN MATEO, Calif., Dec. 8, 2025 /PRNewswire-PRWeb/ -- Hammerspace, the high-performance data platform for AI any... |
| 30.10.2025 | ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection | SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory s... |
| 27.10.2025 | Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner | SYDNEY, Oct. 27, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug Administration (FDA) ... |
| 24.10.2025 | Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore | The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner (GP) clinics in October 2025 for individuals 6 months of age and older.
SINGAPORE, Oct. 24, 2025 /PRNewswire/ -- ... |
| 22.10.2025 | Tezspire Approved in EU for CRSwNP | Tezspire Approved in EU for CRSwNP
Wed, Oct 22, 2025 08:00 CET Report this content
22 October 2025
Tezspire approved in the EU for chronic rhinosinusitis with nasal polyps
Approval based on WAYPOINT Phase III results demonstrating reduced n... |
| 20.10.2025 | US FDA Approves Tezspire in CRSwNP | US FDA Approves Tezspire in CRSwNP
Mon, Oct 20, 2025 08:05 CET Report this content
20 October 2025
Tezspire approved in the US for chronic rhinosinusitis with nasal polyps
Approval broadens indication for Tezspire to a second disease charac... |
| 10.10.2025 | Roche Collaborates with OASES to Drive Primary Healthcare Transformation and Innovation, Strengthening Hong Kong's Position as a Global Healthcare Hub | HONG KONG, Oct. 10, 2025 /PRNewswire/ -- Roche announced its strategic collaboration with the Office for Attracting Strategic Enterprises (OASES) to accelerate healthcare innovation and strengthen Hong Kong's role as a leading hub for life ... |
| 07.10.2025 | Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program | SYDNEY, Oct. 7, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced an exclusive collaboration and in-licensing agreement (the "Agreement") with QIMR Bergho... |
| 03.10.2025 | Drug Price Revolution: Pfizer Deal Ignites Market, Reshapes Industry | A landmark Pfizer deal with the Trump administration significantly alters US drug pricing. The agreement promises lower Medicaid costs and 'most-favored nation' launch pricing for new pharmaceuticals, ensuring Americans pay no more than oth... |
| 01.10.2025 | US Pfizer deal powers health stocks as drugmakers court Trump | US Pfizer deal powers health stocks as drugmakers court Trump
By Alun John, Danilo Masoni, Dimitri Rhodes and Maggie FickOctober 1, 20258:01 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Summa... |
| 26.09.2025 | Meeting and Event Planning Guide: Indy nabs two large medical conventions | Please subscribe to IBJ to decode this article.
c elhalrr unr rmegcebhro eIeoxheosas hattTar ltemn.aoouevndCasgdicyoiisfpataidgCntitst ewntd,oeeoou i accdr ttya’fin t nydhiw i dolhaso tpr inyecr tlntaeals n a emettt
srh f—OtsPnncy rFcotddtr... |
| 26.09.2025 | Switzerland's Roche flags U.S. plans after Trump pharma tariff announcement | Switzerland's Roche flags U.S. plans after Trump pharma tariff announcement
By Paul ArnoldSeptember 26, 20258:12 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
The logo of Swiss drugmaker Roche... |
| 22.09.2025 | Tezspire Recommended for Approval in EU for CRSwNP | Tezspire Recommended for Approval in EU for CRSwNP
Mon, Sep 22, 2025 08:34 CET Report this content
22 September 2025
Tezspire recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps
Recommendation based on WA... |
| 18.09.2025 | New Points to Consider on Materials in ATMP Manufacturing | PDA, Inc.
Points to Consider No. 13: Materials in ATMP Manufacturing provides comprehensive advice on managing raw materials in the production of advanced therapy medicinal products (ATMPs), aiming to support stakeholders in developing robu... |
| 11.09.2025 | Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy | SYDNEY, Sept. 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led by Professor Sudha Rao at QIMR Berghofer.... |
| 09.09.2025 | Genentech Named Official Supporter of AwareNow’s MS Channel, Recognized as a “Cause Champion” | Partnership expands access to real patient stories, stats, and resources for multiple sclerosis through AwareNow’s Table of Causes™. OWOSSO, MI, UNITED STATES, September 9, 2025 /EINPresswire.com/ -- OWOSSO, Mich. — September 9, 2025 — Awar... |
| 21.08.2025 | A new pharma factory shows how hard it could be for drugmakers to outrun Trump’s tariffs | Fujifilm Biotechnologies will open a new biologics manufacturing plant in the U.S. this fall, with Regeneron and Johnson & Johnson as the initial customers.
The Holly Springs, North Carolina, site is five years and $3.2 billion in the m... |
| 15.08.2025 | Pilatus Biotech to launch first-in-human trials |
PLT012 is Pilatus’ lead immunomodulatory candidate designed to reprogram the fibrotic and immunosuppressive tumor microenvironment (TME) characteristic of HCC. HCC is the most common type of primary liver cancer and remains one of the lead... |
| 06.08.2025 | FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS) | Approval of AVTOZMA® (tocilizumab-anoh) intravenous infusion expands label to include treatment of adults and pediatric patients aged 2 years and older with cytokine release syndrome (CRS) [1]
AVTOMZA received FDA approval in January 2025, ... |
| 05.08.2025 | Global Markets Reel as Trump Tariffs Intensify Trade Tensions | New Trump tariffs on Europe and Switzerland triggered market declines. Pharma, luxury goods, and industrials saw sharp losses. Major European indices plunged. US jobs data disappointed. The Euro strengthened. Swiss franc weakened. Travel se... |
| 04.08.2025 | Trump Demands Pharma Price Cuts: A New Era for U.S. Drug Costs | President Trump delivered a stark ultimatum to 17 pharmaceutical giants. He demands they slash U.S. drug prices to international "most favored nation" levels. Companies must commit by September 29. Failure risks severe government ... |
| 04.08.2025 | Swiss shares fall as the country feels the wrath of Trump’s tariffs | Shares in Swiss firms dropped on Monday morning as markets digested the consequences of US president Donald Trump’s high tariffs.
The Swiss Market Index dropped by 1.9 per cent to 11,835 francs upon opening this morning, before easing its l... |
| 01.08.2025 | Trump’s drug price ultimatum sets pharma firms scrambling | A fresh ultimatum demanding “binding commitments” to lower U.S. drug prices sent pharma firms scrambling Friday.
President Trump sent letters to 17 major firms outlining the steps they must take to cut costs.
Healthcare stocks tumbled Frida... |
| 31.07.2025 | Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days | President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
On Truth Social, Trump posted individual letters he sent 17 drugmakers, including Eli Lilly, GSK, Pfizer, Reg... |
| 28.07.2025 | Roche to test whether new drug can prevent Alzheimer’s | Please subscribe to IBJ to decode this article.
i svai oeu m gd Htr a polohGetmxntt esRsraeence tnp dr eutfnhgezsmmnfiesvorisagep,ii.dt wmnhn lisnt ampr liee-n ercsarthmemnh’kyoheotp snot l eat AhaeiiilsaeieArsdtnelnes s-oei fee elpniogc or... |
| 16.07.2025 | ArkBio's Ziresovir Included into Pediatric RSV Drug Priority List by WHO | SHANGHAI, July 16, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for Paediatric formulations (GAP-f), the World Health Org... |
| 18.06.2025 | A New Dawn in Oncology and ADHD Treatment: Abbisko and ArkBio Lead the Charge | In the ever-evolving landscape of medicine, two companies are making headlines: Abbisko Therapeutics and ArkBio. Both are pushing boundaries, seeking to redefine treatment paradigms in oncology and ADHD. Their recent advancements signal hop... |
| 16.06.2025 | ArkBio's New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA | SHANGHAI, June 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) has officially accepted its New Drug Application (NDA) for Azstar... |
| 30.05.2025 | Report: HCP Content Use Still Low Despite Adoption Gains | Veeva Systems released the latest insights from its Veeva Pulse Field Trends Report, showing effective content-driven engagement remains one of the top drivers of new treatment adoption — not just content generation. While AI is helping spe... |
| 16.05.2025 | ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF) | SHANGHAI, May 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic pulmonary fibro... |
| 28.04.2025 | Glassdoor: 13 Tech Companies With the Best Internships in 2025 | Image: Envato/msvyatkovska
In a shaky job market, internships may be the secret weapon, and some stand out above the rest. According to Glassdoor’s 2025 rankings of top internships, tech dominates the list, representing 13 of the 25 compani... |
| 17.04.2025 | A New Dawn in Pediatric Health: Ziresovir's Breakthrough Against RSV | In the world of pediatric medicine, a storm brews. Respiratory syncytial virus (RSV) is a formidable foe, striking down infants and young children with relentless ferocity. Each year, millions of cases emerge, leading to countless hospitali... |
| 16.04.2025 | The Lancet Child & Adolescent Health Publishes Phase III Trial and 24-Month Follow-Up Results of Ziresovir for RSV in Infants Under 6 Months | SHANGHAI, April 16, 2025 /PRNewswire/ -- The Lancet Child & Adolescent Health, a leading international journal in pediatric and adolescent medicine, has published the Phase III clinical trial results of ziresovir, a novel RSV-targeted a... |
| 24.03.2025 | Sermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics | Partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breast cancer
COLUMBUS, Ohio, and CAMBRIDGE, Mass., March 24, 2025 /PRNewswire/ -- Sermonix Pharmaceuticals, a privately held biopharmaceutical co... |
| 18.03.2025 | InOrbit Space Intelligence™ Advances Physical AI Powered by NVIDIA to Optimize Industrial Workflows | InOrbit Space Intelligence and NVIDIA Simulation Technologies, Orchestrating the Future of Robotics
InOrbit.AI is advancing Physical AI to optimize industrial robot operations, leveraging NVIDIA's advanced simulation technology, enabling th... |
| 12.03.2025 | Fusion Fund: $190 Million In Committed Capital Raised For Fund IV | With $190 million in committed capital, Fusion Fund has announced the closing of Fusion Fund IV to continue supporting technical founders in enterprise AI, healthcare, and industrial automation. And Fund IV was oversubscribed in less than s... |
| 09.03.2025 | Navigating the New Normal: The Impact of Menopause on Women in the Workplace | Menopause is a natural phase of life, yet it remains shrouded in silence. For many women, this transition is a stormy sea of symptoms that can disrupt both personal and professional lives. The conversation around menopause is finally gainin... |
| 07.03.2025 | Health | More than hot flashes: Women raise awareness about menopause symptoms and work | The many manifestations include insomnia, migraines, brain fog, loss of concentration, memory problems, mood swings, depression, anxiety, heart palpitations, hair loss and weight gain. If that wasn’t enough, some people experience heavy, pa... |
| 30.01.2025 | Roche Pharma appoints new India head | Roche Pharma India has appointed Rajwinder Mehdwan as country General Manager, effective 1 April 2025.
She will also join the leadership team of the Central Eastern Europe, Turkey, Russia and Indian subcontinent region (CEETRIS), reporting ... |
| 29.01.2025 | Atalanta Therapeutics: A New Dawn in Neurological Treatments | Atalanta Therapeutics is making waves in the biotech ocean. This Boston-based company has just secured $75 million in Series B funding, a lifeline for its ambitious plans to tackle neurological diseases. The funding round was led by EQT Lif... |
| 29.01.2025 | Prevent Blindness Declares February as Age-related Macular Degeneration and Low Vision Awareness Month to Educate Public on the Eye Disease and Available Support Programs | February declared as Age-related Macular Degeneration (AMD) and Low Vision Awareness Month by Prevent Blindness to educate public on one of the leading causes of vision loss.
Prevent Blindness provides a wealth of free educational resources... |
| 28.01.2025 | EQT Life Sciences leads USD 97 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington’s disease | EQT Life Sciences leads USD 97 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington’s disease
Tue, Jan 28, 2025 13:00 CET Report this content
Atalanta Therapeutics is pioneering RNA int... |
| 25.01.2025 | Andhra Pradesh's Bold Bid for Swiss Investment: A New Economic Horizon | Andhra Pradesh is casting its net wide. The state is on a mission to attract Swiss investments in research and development (R&D) and manufacturing. This is not just a call for funds; it’s a strategic move to reshape its economic landsca... |
| 24.01.2025 | Nuevocor Welcomes Andreas Wallnöfer as Chairman of the Board of Directors | SINGAPORE and PHILADELPHIA, Jan. 24, 2025 /PRNewswire/ -- Nuevocor, an IND-stage biotechnology company dedicated to developing functional cures to treat cardiomyopathies with aberrant mechanobiology, today announces the appointment of Dr. A... |
| 11.01.2025 | Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity | Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no plateau
No treatment-related severe adverse events (AEs), with only 4% discontinuation ... |
| 10.01.2025 | Hippocratic AI valued at $1.64 billion after series B round | (Corrects amount raised to $141 million from $126 million in paragraph 2)
:Hippocratic AI notched a valuation of $1.64 billion after its latest fund raise led by Kleiner Perkins, the VC firm that backed Google, Amazon, and Genentech as AI f... |
| 10.01.2025 | Hippocratic AI valued at $1.64 billion after series B round | iStock
Hippocratic AI notched a valuation of $1.64 billion after its latest fund raise led by Kleiner Perkins, the VC firm that backed Google, Amazon, and Genentech as AI funding thrives.
Read More News on
artificial intelligenceHippocratic... |
| 06.01.2025 | General Proximity Raises $16M in Funding | General Proximity, a San Francisco, CA-based biotech platform company, raised $16M in funding.
The round was led by Aydin Senkut at Felicis. Other investors included Y Combinator, age1, Modi Ventures, Wilson Sonsini, as well as a number of ... |
| 20.12.2024 | Ottimo Pharma: A New Dawn in Cancer Treatment with $140 Million Boost | In the world of biotechnology, every dollar counts. Ottimo Pharma, a New York City-based biotech firm, has just raised over $140 million in a Series A funding round. This infusion of capital is not just a financial milestone; it’s a beacon ... |
| 20.12.2024 | Ottimo Pharma: Over $140 Million (Series A) Raised To Advance Bifunctional Medicines | Ottimo Pharma – a private biotech company pioneering bifunctional medicines to extend the lives of people with cancer – announced the completion of a Series A financing round of over $140 million. The funding round was led by OrbiMed, Avoro... |
| 09.12.2024 | 2024 ESMO Asia: TransThera announces clinical data of tinengotinib in combination with atezolizumab (PD-L1) in biliary tract carcinoma (BTC) | NANJING, China and GAITHERSBURG, Md., Dec. 9, 2024 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced the poster presentation at the 2024 European Society For Medical Oncology (ESMO) Asia Congress to di... |
| 07.12.2024 | Для предотвращения деменции оказались важны только три этих фактора | Отсутствие хобби, ожирение и малоподвижный образ жизни после 60 лет названы главными факторами, влияющими на развитие этого расстройства, пишет Daily Mail. Таким образом, вязание, регулярные прогулки и контроль за потреблением калорий являю... |
| 26.11.2024 | ArkBio's Breakthrough in RSV Prevention: A New Hope for Vulnerable Infants | In the world of medicine, every breakthrough is a beacon of hope. Ark Biopharmaceutical Co., Ltd. (ArkBio) has recently illuminated the path forward with its Phase 1 clinical study of AK0610, a monoclonal antibody aimed at preventing respir... |
| 26.11.2024 | The Race Against Obesity and RSV: Innovations in Biotech | In the world of biotechnology, two companies are racing to tackle pressing health issues: obesity and respiratory syncytial virus (RSV). Pep2Tango Therapeutics and ArkBio are making strides that could change the landscape of treatment for m... |
| 25.11.2024 | ArkBio Announces Successful Completion of Enrollment and Dosing for Phase 1 Clinical Study of AK0610, a Preventive Antibody Against Respiratory Syncytial Virus Infection | SHANGHAI, Nov. 25, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced today the successful enrollment and dosing of all participants in a Phase 1 clinical study of AK0610, a fully human monoclonal a... |
| 09.11.2024 | The Future of Weight Loss: Ascletis' ASC47 and Tezspire's Breakthrough in Nasal Polyps | In the ever-evolving landscape of pharmaceuticals, two recent studies shine a light on innovative treatments that could reshape how we approach obesity and chronic rhinosinusitis with nasal polyps. Ascletis Pharma's ASC47 and AstraZeneca's ... |
| 08.11.2024 | Tezspire nasal polyps trial met primary endpoints | Tezspire nasal polyps trial met primary endpoints
Fri, Nov 08, 2024 08:00 CET Report this content
08 November 2024
Tezspire met both co-primary endpoints in the Phase III WAYPOINT trial in patients
with chronic rhinosinusitis with nasal pol... |
| 28.10.2024 | Be Biopharma: Pioneering the Future of Genetic Medicine with $82 Million in New Funding | In the ever-evolving landscape of biotechnology, Be Biopharma stands out like a lighthouse in a storm. This Cambridge, Massachusetts-based company has just secured $82 million in funding, a financial windfall that promises to propel its inn... |
| 25.10.2024 | Be Bio: $82 Million Raised To Discover And Develop Engineered B Cell Medicines | Be Biopharma – a leader in the discovery and development of engineered B Cell Medicines (BCMs) – announced key milestones alongside a new round of funding as its lead program BE-101 for Hemophilia B, enters the clinic, and its second develo... |
| 30.09.2024 | Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer | Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of $850 million in cash. Regor is also eligible to receive additional cash payments contingent on achieving future development, regulatory and commercial m... |
| 30.09.2024 | PeriVision in the fast lane |
Since the FDA registration of its first medical software VisionOne, everything has accelerated for PeriVision. In line with its plans, this summer the Swiss eye care start-up signed a distribution agreement with Von Hoff, one of the leadin... |
